- Home
- KLRS
as 05-08-2025 3:38pm EST
Kalaris Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing therapeutics. Kalaris is developing TH103, a novel, clinical stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body native, highest affinity VEGF receptor 1.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 129.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 62.9K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -10.44 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.19 - $24.15 | Next Earning Date: | 05-19-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Kalaris Therapeutics Inc. Common Stock News
KLRS Breaking Stock News: Dive into KLRS Ticker-Specific Updates for Smart Investing
Compare KLRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "KLRS Kalaris Therapeutics Inc. Common Stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.